Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.

Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.

Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.

Milind Desai and C. Michael Gibson compare the results of mavacamten for severe obstructive hypertropic cardiomyopathy with the typical treatments of surgical septal myectomy or alcohol ablation.

Justin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.

Shamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.

Tijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.

Mark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.

Gregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.

Javed Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.